Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CovCP) infusions
have been widely used for the treatment of hospitalized patients with COVID-19. The aims of …

Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and
effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a …

Background: The rapidly evolving coronavirus disease 2019 (COVID-19) has resulted in
more than 24 million infections and 821 thousand deaths. However, a vaccine or specific …

The use of convalescent plasma (CP) transfusions for patients with coronavirus disease
2019 (COVID-19) has gained great interest during the severe acute respiratory syndrome …

The collection and clinical use of COVID-19 convalescent plasma (CCP) as a therapy for
COVID-19 infection is under development and early use in many centers worldwide. We …

Objective To study the effectiveness of COVID-19 convalescent plasma (CCP) therapy for
patients with moderate and severe COVID-19 disease. Methods This non-randomized …

Background Two years into the pandemic, convincing evidence in favour of convalescent
plasma (ConvP) as a treatment for coronavirus disease 2019 (COVID-19) is still lacking. This …

Background Convalescent plasma (CP) has been widely used to treat COVID-19 and is
under study. However, the variability in the current clinical trials has averted its wide use in …

Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the
treatment for other emerging viral infections. However, the quality control of CP and …

Background and objectives Use of convalescent plasma for coronavirus disease 2019
(COVID‐19) treatment has gained interest worldwide. However, there is lack of evidence on …